IN2014DN01959A - - Google Patents

Download PDF

Info

Publication number
IN2014DN01959A
IN2014DN01959A IN1959DEN2014A IN2014DN01959A IN 2014DN01959 A IN2014DN01959 A IN 2014DN01959A IN 1959DEN2014 A IN1959DEN2014 A IN 1959DEN2014A IN 2014DN01959 A IN2014DN01959 A IN 2014DN01959A
Authority
IN
India
Prior art keywords
prostate cancer
levels
castration resistant
reducing
resistant prostate
Prior art date
Application number
Other languages
English (en)
Inventor
James Dalton
Mitchell S Steiner
Christopher C Coss
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/215,679 external-priority patent/US9427418B2/en
Application filed by Gtx Inc filed Critical Gtx Inc
Priority claimed from PCT/US2012/052141 external-priority patent/WO2013043304A1/en
Publication of IN2014DN01959A publication Critical patent/IN2014DN01959A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
IN1959DEN2014 2011-08-23 2012-08-23 IN2014DN01959A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/215,679 US9427418B2 (en) 2009-02-23 2011-08-23 Estrogen receptor ligands and methods of use thereof
PCT/US2012/052141 WO2013043304A1 (en) 2009-02-23 2012-08-23 Estrogen receptor ligands and methods of use thereof

Publications (1)

Publication Number Publication Date
IN2014DN01959A true IN2014DN01959A (cg-RX-API-DMAC7.html) 2015-05-15

Family

ID=48444651

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1959DEN2014 IN2014DN01959A (cg-RX-API-DMAC7.html) 2011-08-23 2012-08-23

Country Status (10)

Country Link
EP (1) EP2747562A4 (cg-RX-API-DMAC7.html)
JP (1) JP2014524479A (cg-RX-API-DMAC7.html)
KR (1) KR20140064906A (cg-RX-API-DMAC7.html)
CN (1) CN103957706A (cg-RX-API-DMAC7.html)
AU (1) AU2012312902B2 (cg-RX-API-DMAC7.html)
CA (1) CA2845890A1 (cg-RX-API-DMAC7.html)
IL (1) IL231070A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN01959A (cg-RX-API-DMAC7.html)
MX (1) MX2014002105A (cg-RX-API-DMAC7.html)
RU (1) RU2014111060A (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3688008A1 (en) * 2017-09-27 2020-08-05 TargImmune Therapeutics AG Castration resistant prostate cancer
SG11202107712SA (en) * 2019-01-30 2021-08-30 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
US20230174662A1 (en) * 2019-02-01 2023-06-08 Fondazione Per L'istituto Oncologico Di Ricerca (Ior) Methods of treating castrate-resistant prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
CA2824517A1 (en) * 2005-11-28 2007-05-31 Gtx, Inc. Nuclear receptor binding agents
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
WO2010096801A1 (en) * 2009-02-23 2010-08-26 Gtx, Inc. Estrogen receptor ligands and methods of use thereof

Also Published As

Publication number Publication date
RU2014111060A (ru) 2015-09-27
EP2747562A4 (en) 2015-05-06
CN103957706A (zh) 2014-07-30
MX2014002105A (es) 2014-09-25
AU2012312902B2 (en) 2016-03-17
AU2012312902A1 (en) 2013-05-23
JP2014524479A (ja) 2014-09-22
KR20140064906A (ko) 2014-05-28
IL231070A0 (en) 2014-03-31
CA2845890A1 (en) 2013-03-28
EP2747562A1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
MX340753B (es) Ligandos de receptor de estrogeno y metodos de uso de los mismos.
IN2015DN01046A (cg-RX-API-DMAC7.html)
MX2016001901A (es) Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
MX2021002406A (es) Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica.
MX2010003013A (es) Inhibicion de angiogenesis.
SI2444085T1 (sl) Diarilhidantoinske spojine kot antagonisti androgenega receptorja za zdravljenje raka
IN2012DN02046A (cg-RX-API-DMAC7.html)
IL218987A0 (en) Methods and compositions for treating cancer
MX2013009732A (es) Terapias de combinacion comprendiendo agentes anti-erbb3.
MY193562A (en) Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
WO2012078633A8 (en) Methods of inhibiting metastasis from cancer
PH12014502048B1 (en) Treatment of cancer with tor kinase inhibitors
MX360774B (es) Antagonistas de progesterona.
PH12012500916B1 (en) Treatments for gastrointestinal disorders
WO2011011692A3 (en) Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle)
PH12014502046A1 (en) Treatment of cancer with tor kinase inhibitors
WO2011129936A3 (en) Compositions and methods for the prevention and treatment of cancer
PH12015502342B1 (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
MY150600A (en) Use of opioid antagonists for treating urinary retention
MX2013010530A (es) Combinacion de oligonucleotido anti-clusterina con antagonistas del receptor de androgeno para el tratamiento de cancer de prostata.
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
EP4034682C0 (en) DIRECT REDUCTION PROCESS USING HYDROGEN
PH12012500911A1 (en) Methods and compositions for treating solid tumors and other malignancies
MX2019013864A (es) Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo.
IL253853A0 (en) Methods and preparations for the treatment or prevention of symptoms of hormonal changes